J Formos Med Assoc
-
Case Reports
Evolution of SARS-CoV-2 neutralizing antibody in an HIV-positive patient with COVID-19.
We presented the clinical course and immune responses of a well-controlled HIV-positive patient with COVID-19. The clinical presentation and antibody production to SARS-CoV-2 were similar to other COVID-19 patients without HIV infection. Neutralizing antibody reached a plateau from 26th to 47th day onset but decreased on 157th day after symptoms.
-
A modified novel analytical method for evaluating photographic retinal nerve fiber layer defect (RNFLD) was developed for the purpose of estimating the severity of early glaucomatous eyes. This new method was then compared with the original method, as described below, in relation to the visual field defect severity. ⋯ Our novel method was more convenient in a clinical setting and noninferior to the original method.